Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,077.1
-34.0 (-1.09%)

 

  • STI Straits Times Index
    3,077.1
    -34.0 (-1.09%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,662.0
    -14.0 (-0.84%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,094.8
    -429.6 (-1.62%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,593.7
    -40.3 (-1.53%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,374.8
    -441.4 (-2.02%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,169.8
    -7.9 (-0.13%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,069.4
    -26.2 (-1.25%)
    Index delayed 20 minutes
  • XAO XAO
    5,678.8
    -56.5 (-0.99%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 586.6M
  • Value: 808.5M
  • Rise: 115
  • Fall: 190
  • Unch: 537

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
MMP Resources^0.007-
Ezion0.049-0.003
LionGold0.001-
SingTel3.040-0.040
ThaiBev0.590-0.015
Rex Intl0.060-0.003
SingHaiyi0.080-0.001
Genting Sing0.995-0.015
QT Vascular0.008-
YZJ Shipbldg SGD1.210-0.020

World Indices

World Indices
Name Last Change
Nasdaq 6,910.7 -159.7
HSI 26,094.8 -429.6
HSCEI 10,359.4 -197.4
Jakarta 6,169.8 -7.9
Nikkei 225 21,374.8 -441.4
SSE Comp 2,593.7 -40.3
Shanghai A 2,716.0 -42.2
Shanghai B 279.4 -2.9
ShenZhen A 1,388.0 -35.1
ShenZhen B 856.3 -9.1
Taiwan W 9,774.2 -84.6
PSE Comp 0.0
KOSPI 2,069.4 -26.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Tianjin ZX USD TIANJIN ZHONG XIN PHARM GROUP
Quotes 10 Minutes Delayed. Updated at 14 Dec 2018 17:04
Last (USD): 0.875 Change: +0.010 High: 0.885 Remarks: -
Change (%): +1.16 Low: 0.865
Open 0.865 Yesterday's Close 0.865
Buy Price 0.875 Sell Price 0.880
Buy Volume ('000) 9.5 Sell Volume ('000) 26.7
Cumulative Volume ('000) 536.4 Cumulative Value 471,028
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 0.09498 Trailing EPS (USD) e 0.10676 NAV (USD) b 0.8893
PE a 9.212 Trailing PE f 8.196 Price / NAV b 0.9839
Dividend (USD) d 0.030680 Cash In Hand (USD) g 0.2296 Issued & Paid-up Shares c 200,000,000
Dividend Yield (%) d 3.506 Price / Cash In Hand g 3.811 Treasury Shares h -
Beta - 75 Daysi 1.062 R-Squared - 75 Days(%)i 29.69 Market Cap (M) 672.764
Beta - 500 Daysi 0.682 R-Squared - 500 Days (%)i 5.99 Enterprise Value (M) 546.794
Piotroski F Score 7 Exchange Code T14 Par Value ( RMB ) 1.00000
52 Weeks Volatility (%) 31.9465 6-Month VWAP 1.011 Free Float (%) 92.4
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Pharmaceuticals: Other
Category Classification China / Medical & Biotechnology
Index Components FTSE ST All-Share Index / FTSE ST China Index / FTSE ST Fledgling Index / FTSE ST Health Care Index / FTSE ST Small Cap Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 25 Jun 2018.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Tianjin ZX USD SGX 672.764 9.212 8.196 0.9839 3.506
Industry China SGX 619.397 11.526 10.555 0.7354 3.692
Medical & Biotechnology SGX 1,154.554 22.695 21.005 1.4325 1.713
Pharmaceuticals: Other SGX 347.780 12.858 11.100 1.0555 3.112
Index FTSE ST All-Share Index SGX 5,247.342 11.888 14.033 1.1906 3.405
FTSE ST China Index SGX 3,221.516 5.033 6.131 0.5983 3.840
FTSE ST Fledgling Index SGX 85.700 32.994 22.861 0.6890 2.968
FTSE ST Health Care Index SGX 944.942 18.300 17.904 2.2188 2.197
FTSE ST Small Cap Index SGX 639.490 1587.376 15.463 0.9738 6.245
Local Peer IX Biopharma SGX 109.490 - - 5.8621 -
Local Peer Star Pharm^ SGX 7.923 - - 0.2764 -
Global Peer JAZZ PHARMACEUTICALS PLC NASDAQ 8,478.860 17.380 16.311 2.8008 -
Global Peer BAUSCH HEALTH COMPANIES INC NYSE 7,999.720 3.328 - 2.3062 -
Global Peer FOSUN PHARMA HKEx 60,744.546 16.860 18.035 1.8722 1.889
Global Peer PERRIGO COMPANY PLC NYSE 7,742.490 64.736 63.101 1.3680 1.164
Global Peer ICON NASDAQ 7,267.206 25.817 23.780 5.4457 -
Global Peer SH PHARMA HKEx 49,281.893 12.140 9.802 1.1243 2.517
Global Peer Kalbe Farma Tbk. IDX 69,843,899.000 29.058 28.759 5.0125 1.678
Global Peer CATALENT INC NYSE 5,035.686 60.235 76.998 3.2926 -
Global Peer SAGE THERAPEUTICS INC NASDAQ 4,782.005 - - 4.8376 -
Global Peer AMARIN CORP ADR EACH REP 1 ORD GBP0.50 NASDAQ 4,714.959 - - -63.1289 -
Other Global Peers UNITED THERAPEUTICS CORP (NASDAQ), ARGENX SE SPON ADR EACH REP 1 ORD SHS (NASDAQ), GW PHARMACEUTICALS ADS EA REPR 12 ORD GBP0.00 (NASDAQ), HORIZON PHARMA PLC (NASDAQ), INTERCEPT PHARMACEUTICALS INC (NASDAQ), LUYE PHARMA (HKEx), SSY GROUP (HKEx), ENDO INTERNATIONAL PLC (NASDAQ), LIVZON PHARMA (HKEx), SIHUAN PHARM (HKEx), MYOKARDIA INC (NASDAQ), CRONOS GROUP INC (NASDAQ), SUPERNUS PHARMACEUTICALS INC (NASDAQ), PACIRA PHARMACEUTICALS INC (NASDAQ), CORCEPT THERAPEUTICS INC (NASDAQ), IRONWOOD PHARMACEUTICALS INC (NASDAQ), TONG REN TANG (HKEx), AURORA CANNABIS INC (NYSE), ZOGENIX INC (NASDAQ), AERIE PHARMACEUTICALS INC (NASDAQ), INNOVIVA INC (NASDAQ), MADRIGAL PHARMACEUTICALS INC (NASDAQ), PRESTIGE CONSUMER HEALTHCARE INC (NYSE), HEC PHARM (HKEx), MALLINCKRODT PLC (NYSE), BLACKMORES LTD (ASX), CHINAGRANDPHARM (HKEx), THERAVANCE BIOPHARMA INC (NASDAQ), MEDICINES CO (NASDAQ), PORTOLA PHARMACEUTICALS INC (NASDAQ), Indofarma Tbk. (IDX), Kimia Farma Tbk. (IDX), AMPHASTAR PHARMACEUTICALS INC (NASDAQ), INTERSECT ENT INC (NASDAQ), MEGA (SET), REVANCE THERAPEUTICS INC (NASDAQ), EAGLE PHARMACEUTICALS INC (NASDAQ), ANI PHARMACEUTICALS INC (NASDAQ), CLINUVEL PHARMACEUTICALS LTD (ASX), COLLEGIUM PHARMACEUTICAL INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), ASSEMBLY BIOSCIENCES INC (NASDAQ), CONSUN PHARMA (HKEx), APHRIA INC (NYSE), OSIRIS THERAPEUTICS INC (NASDAQ), Tempo Scan Pacific Tbk. (IDX), FUDANZHANGJIANG (HKEx), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), ANIKA THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), ARQULE INC (NASDAQ), MEI PHARMA INC (NASDAQ), ACLARIS THERAPEUTICS INC (NASDAQ), SHANDONG XINHUA (HKEx), ALBIREO PHARMA INC (NASDAQ), INTEC PHARMA LTD (NASDAQ), ADAMAS PHARMACEUTICALS INC (NASDAQ), BIODELIVERY SCIENCES INTERNATIONAL (NASDAQ), CATALYST PHARMACEUTICALS INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), OASMIA PHARMACEUTICAL AB ADR EACH REP 3 ORD SHS (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), FOAMIX PHARMACEUTICALS LTD (NASDAQ), ACELRX PHARMACEUTICALS INC (NASDAQ), ELIXINOL GLOBAL LTD (ASX), OCI INTL (HKEx), GALMED PHARMACEUTICALS LTD (NASDAQ), DOD (SET), MARINUS PHARMACEUTICALS INC (NASDAQ), VERONA PHARMA SPON ADR EACH REP 8 ORD SHS (NASDAQ), IMPRIMIS PHARMACEUTICALS INC (NASDAQ), CERECOR INC (NASDAQ), MEDIWOUND LTD (NASDAQ), SANAI HEALTH GP (HKEx), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), GOLDEN THROAT (HKEx), DURECT CORP (NASDAQ), NEOS THERAPEUTICS INC (NASDAQ), OPTHEA LIMITED (ASX), CUMBERLAND PHARMACEUTICALS INC (NASDAQ), AXSOME THERAPEUTICS INC (NASDAQ), YSPSAH (Bursa), TETRAPHASE PHARMACEUTICALS INC (NASDAQ), ZYNERBA PHARMACEUTICALS INC (NASDAQ), ACHAOGEN INC (NASDAQ), JILIN CHANGLONG (HKEx), CTI BIOPHARMA CORP (NASDAQ), PHARMAXIS (ASX), ORAMED PHARMACEUTICALS INC (NASDAQ), INVION LTD (ASX), MELINTA THERAPEUTICS INC (NASDAQ), BIOLINE RX LTD SPON ADS EACH REPR 10 ORD SHS (NASDAQ), TIANDA PHARMA (HKEx), KEMPHARM INC (NASDAQ), COGSTATE (ASX), LANSEN PHARMA (HKEx), EVOKE PHARMA INC (NASDAQ), THC GLOBAL GROUP LTD (ASX), BOTANIX PHARMACEUTICALS LTD (ASX), VITA LIFE SCIENCES LIMITED (ASX), EAGLE HEALTH HOLDINGS LTD (ASX), ACASTI PHARMA INC (NASDAQ), PLX PHARMA INC (NASDAQ), VIVUS INC (NASDAQ), LIPOCINE INC (NASDAQ), ALTHEA GROUP HOLDINGS LTD (ASX), AMPIO PHARMACEUTICALS INC (NYSE American), AGILE THERAPEUTICS (NASDAQ), C HEALTH GP (HKEx), IDT AUSTRALIA LIMITED (ASX), SCYNEXIS INC (NASDAQ), EYEGATE PHARMACEUTICALS INC (NASDAQ), ACRUX (ASX), SYNERGY PHARMACEUTICALS INC DEL (NASDAQ), PAIN THERAPEUTICS (NASDAQ), CYTRX CORP (NASDAQ), MY SIZE INC (NASDAQ), BAYTACARE PHARM (HKEx), REGULUS THERAPEUTICS INC (NASDAQ), MYOS RENS TECHNOLOGY INC (NASDAQ), CANNPAL ANIMAL THERAPEUTICS LTD (ASX), ANTISENSE THERAPEUTICS (ASX), APRICUS BIOSCIENCES INC (NASDAQ), Pyridam Farma Tbk (IDX), CONTRAVIR PHARMACEUTICALS INC (NASDAQ), FLEX PHARMA INC (NASDAQ), ARADIGM CORP (NASDAQ), PERNIX THERAPEUTICS HOLDINGS INC (NASDAQ), PHARMAUST LIMITED (ASX), SONOMA PHARMACEUTICALS INC (NASDAQ), RITTER PHARMACEUTICALS INC (NASDAQ), TONIX PHARMACEUTICALS HLDG CORP (NASDAQ), LONGRUN TEA (HKEx), HUA HAN HEALTH (HKEx), C ANIMAL HEALTH (HKEx)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.015
-1.69 %
10 Days ---
20 Days --0.010
-1.13 %
Medium Term Return 3 Months --0.045
-4.89 %
6 Months 0.030-0.255
-19.91 %
1 Year 0.030-0.055
-2.69 %
Long Term Return 2 Years 0.052+0.040
+11.02 %
3 Years 0.089-0.220
-11.96 %
5 Years 0.122-0.215
-8.53 %
Annualised Return Annualised --
-1.77 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.835 - 1.290 Change From 1 Year Low +0.040 % Change From 1 Year Low (%) +4.79
Change From 1 Year High -0.415 % Change From 1 Year High (%) -32.17
2 Years Range 0.825 - 1.290 Change From 2 Years Low +0.050 % Change From 2 Years Low (%) +6.06
Change From 2 Years High -0.415 % Change From 2 Years High (%) -32.17
5 Years Range 0.730 - 1.915 Change From 5 Years Low +0.145 % Change From 5 Years Low (%) +19.86
Change From 5 Years High -1.040 % Change From 5 Years High (%) -54.31
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

In the 1950s, with the China government's policy of merging state-owned pharmaceutical enterprises with the private sector, Tianjin Municipal Chinese Medicinal Materials Corpn (TMCM) merged and reorganised the various factories and stores in Tianjin. In December 1992, TMCM was converted from a state-owned enterprise to a company limited by shares whereby shares were issued to legal persons and its employees. In connection therewith, it was renamed Tianjin Traditional Chinese Medicine Group Co Ltd (TTCM). Following the corporatisation of the Company, the shares issued to the employees were traded at the Tianjin Securities Trading Centre.

In conjunction with the proposed public offering, TTCM adopted its present name. Pursuant to the restructuring, it became the holding company for the Group.

The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese medicinal drinks, Chinese medicinal raw materials, biotechnology medicine, chemical raw material medicine and preparations, and nutritional and health products. It has over 800 medicinal products in over 20 types of formulations. The main products are Suxiao Jiuxin pill (used for treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment of intestines and stomach disease), Gengnian An (used for treatment of menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu Zhuyu capsule (used for treatment of diseases relating to heart and head blood vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of diabetes), and Te Zi She Fu (used for diminishing inflammation).

The holding company and ultimate holding company is Tianjin Pharmaceutical Hldgs, a company incorporated in Tianjin, China.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2017 Dec 2017 Part 1(3.65 MB)
Annual Report 2016 Dec 2016 Part 1(2.98 MB)
Annual Report 2015 Dec 2015 Part 1(2.25 MB)
Annual Report 2014 Dec 2014 Part 1(2.46 MB)
Annual Report 2013 Dec 2013 Part 1(1.87 MB)
Part 2(0.02 MB)
Part 3(0.02 MB)
Annual Report 2012 Dec 2012 Part 1(9.46 MB)
Annual Report 2011 Dec 2011 Part 1(11.18 MB)
Annual Report 2010 Dec 2010 Part 1(5.33 MB)
Annual Report 2009 Dec 2009 Part 1(0.75 MB)
Annual Report 2008 Dec 2008 Part 1(2.38 MB)
Annual Report 2007 Dec 2007 Part 1(1.33 MB)
Annual Report 2006 Dec 2006 Part 1(5.41 MB)
Annual Report 2005 Dec 2005 Part 1(0.68 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
14 Dec 2018 0.865 0.885 0.865 0.875 536,400 0.8781
13 Dec 2018 0.845 0.875 0.845 0.865 404,800 0.8618
12 Dec 2018 0.850 0.860 0.850 0.850 89,400 0.8549
11 Dec 2018 0.850 0.855 0.845 0.850 150,500 0.8512
10 Dec 2018 0.885 0.885 0.835 0.855 928,100 0.8564
07 Dec 2018 0.905 0.905 0.890 0.890 79,200 0.8968
06 Dec 2018 0.910 0.910 0.890 0.900 138,800 0.8972
05 Dec 2018 0.895 0.935 0.895 0.915 312,600 0.9191
04 Dec 2018 0.900 0.920 0.895 0.910 300,200 0.9091
03 Dec 2018 0.890 0.905 0.885 0.900 286,200 0.8973
30 Nov 2018 0.880 0.885 0.875 0.875 51,700 0.8784
29 Nov 2018 0.885 0.895 0.875 0.880 168,800 0.8865
28 Nov 2018 0.865 0.885 0.865 0.880 163,300 0.8806
27 Nov 2018 0.865 0.875 0.860 0.870 55,200 0.8674
26 Nov 2018 0.865 0.875 0.860 0.870 150,600 0.8647
23 Nov 2018 0.865 0.880 0.865 0.870 46,400 0.8706
22 Nov 2018 0.870 0.875 0.865 0.865 153,100 0.8694
21 Nov 2018 0.860 0.875 0.860 0.875 69,700 0.8680
20 Nov 2018 0.875 0.880 0.865 0.865 204,500 0.8720
19 Nov 2018 0.885 0.885 0.875 0.875 199,700 0.8800
16 Nov 2018 0.895 0.900 0.880 0.885 222,800 0.8896
15 Nov 2018 0.885 0.890 0.880 0.885 272,600 0.8859
Summary
Current 2 Weeks
(03 Dec 2018 to 14 Dec 2018)
0.890 0.935 0.835 0.875 3,226,200 -
Previous 2 Weeks
(19 Nov 2018 to 30 Nov 2018)
0.885 0.935 0.835 0.875 1,263,000 -
4 Weeks from
(19 Oct 2018 to 16 Nov 2018)
0.920 0.935 0.835 0.885 6,608,000 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.